251 related articles for article (PubMed ID: 24650865)
1. Drug resistance among tuberculosis cases in the European Union and European Economic Area, 2007 to 2012.
van der Werf MJ; Ködmön C; Hollo V; Sandgren A; Zucs P
Euro Surveill; 2014 Mar; 19(10):. PubMed ID: 24650865
[TBL] [Abstract][Full Text] [Related]
2. Childhood multidrug-resistant tuberculosis in the European Union and European Economic Area: an analysis of tuberculosis surveillance data from 2007 to 2015.
Ködmön C; van den Boom M; Zucs P; van der Werf MJ
Euro Surveill; 2017 Nov; 22(47):. PubMed ID: 29183553
[TBL] [Abstract][Full Text] [Related]
3. Tuberculosis treatment outcome in the European Union and European Economic Area: an analysis of surveillance data from 2002-2011.
Karo B; Hauer B; Hollo V; van der Werf MJ; Fiebig L; Haas W
Euro Surveill; 2015; 20(49):. PubMed ID: 26676247
[TBL] [Abstract][Full Text] [Related]
4. Extensively drug-resistant tuberculosis in the United States, 1993-2007.
Shah NS; Pratt R; Armstrong L; Robison V; Castro KG; Cegielski JP
JAMA; 2008 Nov; 300(18):2153-60. PubMed ID: 19001626
[TBL] [Abstract][Full Text] [Related]
5. Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area.
Ködmön C; Hollo V; Huitric E; Amato-Gauci A; Manissero D
Euro Surveill; 2010 Mar; 15(11):. PubMed ID: 20338147
[TBL] [Abstract][Full Text] [Related]
6. Migration-related tuberculosis: epidemiology and characteristics of tuberculosis cases originating outside the European Union and European Economic Area, 2007 to 2013.
Ködmön C; Zucs P; van der Werf MJ
Euro Surveill; 2016; 21(12):. PubMed ID: 27039665
[TBL] [Abstract][Full Text] [Related]
7. Monitoring the progress achieved towards ending tuberculosis in the European Union/European Economic Area, 2018 to 2021.
Cristea V; Ködmön C; Rosales-Klintz S; Pharris A; van der Werf MJ
Euro Surveill; 2023 Mar; 28(12):. PubMed ID: 36951788
[TBL] [Abstract][Full Text] [Related]
8. Extensively drug-resistant tuberculosis in california, 1993-2006.
Banerjee R; Allen J; Westenhouse J; Oh P; Elms W; Desmond E; Nitta A; Royce S; Flood J
Clin Infect Dis; 2008 Aug; 47(4):450-7. PubMed ID: 18616396
[TBL] [Abstract][Full Text] [Related]
9. Drug-resistant tuberculosis in the WHO European Region: an analysis of surveillance data.
Zignol M; Dara M; Dean AS; Falzon D; Dadu A; Kremer K; Hoffmann H; Hoffner S; Floyd K
Drug Resist Updat; 2013 Dec; 16(6):108-15. PubMed ID: 24631052
[TBL] [Abstract][Full Text] [Related]
10. TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged?
Migliori GB; Sotgiu G; D'Ambrosio L; Centis R; Lange C; Bothamley G; Cirillo DM; De Lorenzo S; Guenther G; Kliiman K; Muetterlein R; Spinu V; Villar M; Zellweger JP; Sandgren A; Huitric E; Manissero D
Eur Respir J; 2012 Mar; 39(3):619-25. PubMed ID: 22323578
[TBL] [Abstract][Full Text] [Related]
11. Epidemiological trends and outcomes of extensively drug-resistant tuberculosis in Shandong, China.
He XC; Tao NN; Liu Y; Zhang XX; Li HC
BMC Infect Dis; 2017 Aug; 17(1):555. PubMed ID: 28793873
[TBL] [Abstract][Full Text] [Related]
12. Anti-tuberculosis drug resistance patterns and trends in a tuberculosis referral hospital, 1997-2009.
Liu CH; Li HM; Li L; Hu YL; Wang Q; Yang N; Wang S; Zhu B
Epidemiol Infect; 2011 Dec; 139(12):1909-18. PubMed ID: 21272420
[TBL] [Abstract][Full Text] [Related]
13. Tuberculosis in Poland in 2017.
Korzeniewska- Koseła M
Przegl Epidemiol; 2019; 73(2):211-226. PubMed ID: 31385679
[TBL] [Abstract][Full Text] [Related]
14. Cost of multi drug resistance tuberculosis in Germany.
Diel R; Nienhaus A; Lampenius N; Rüsch-Gerdes S; Richter E
Respir Med; 2014 Nov; 108(11):1677-87. PubMed ID: 25443398
[TBL] [Abstract][Full Text] [Related]
15. Tuberculosis in Poland in 2021.
Korzeniewska-Koseła M; Wesołowski S
Przegl Epidemiol; 2024 May; 77(4):449-465. PubMed ID: 38783654
[TBL] [Abstract][Full Text] [Related]
16. Resistance patterns among multidrug-resistant tuberculosis patients in greater metropolitan Mumbai: trends over time.
Dalal A; Pawaskar A; Das M; Desai R; Prabhudesai P; Chhajed P; Rajan S; Reddy D; Babu S; Jayalakshmi TK; Saranchuk P; Rodrigues C; Isaakidis P
PLoS One; 2015; 10(1):e0116798. PubMed ID: 25606853
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience.
Liu CH; Li L; Chen Z; Wang Q; Hu YL; Zhu B; Woo PC
PLoS One; 2011 Apr; 6(4):e19399. PubMed ID: 21559362
[TBL] [Abstract][Full Text] [Related]
18. Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.
Mok JH; Kang BH; Lee T; Lee HK; Jang HJ; Cho YJ; Jeon D
J Korean Med Sci; 2017 Apr; 32(4):636-641. PubMed ID: 28244290
[TBL] [Abstract][Full Text] [Related]
19. Surveillance of extensively drug-resistant tuberculosis in Europe, 2003-2007.
Devaux I; Manissero D; Fernandez de la Hoz K; Kremer K; van Soolingen D;
Euro Surveill; 2010 Mar; 15(11):. PubMed ID: 20338144
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: a retrospective hospital-based study.
Sharma SK; George N; Kadhiravan T; Saha PK; Mishra HK; Hanif M
Indian J Med Res; 2009 Oct; 130(4):392-5. PubMed ID: 19942741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
